Balaxi Pharmaceuticals Limited AI Stock Analysis
Want to see IN:BALAXI full AI Analyst Report?
Balaxi Pharmaceuticals Limited (BALAXI) AI Stock Analysis
Balaxi Pharmaceuticals Limited
(NSE:BALAXI)
Overall score is weighed down mainly by weak financial performance—especially sustained negative operating/free cash flow and a sharp FY2026 profitability drop—along with bearish technical conditions (price below key moving averages and negative MACD). Valuation provides limited support given the high P/E and no dividend yield data.
Balaxi Pharmaceuticals Limited (BALAXI) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 1.29B
- Dividend Yield
- ―
- Average Volume (3M)
- 36.35K
- Price to Earnings (P/E)
- 37.9
- Beta (1Y)
- 1.09
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- India
- Employees
- 500
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
Balaxi Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Balaxi Pharmaceuticals Limited, through its entity Balaxi Ventures Ltd., primarily operates as an international wholesale distributor specializing in pharmaceuticals, various food items, and hardware supplies. The company's corporate base is situated...
Balaxi Pharmaceuticals Limited Financial Statement Overview
Summary
Financials are pressured: profitability deteriorated sharply in FY2026 (net margin ~0.5% vs ~8.7% in FY2025) and revenue was slightly down (-1.3% YoY). While leverage is moderate (debt-to-equity ~0.23), cash flow is a major weakness with negative operating cash flow in FY2025–FY2026 and deeply negative free cash flow, increasing funding risk.
Income Statement
46NeutralBalance Sheet
68PositiveCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.73B | 2.73B | 2.89B | 2.41B | 3.36B | 2.79B |
| Gross Profit | 1.20B | 1.14B | 1.27B | 1.13B | 1.34B | 837.91M |
| EBITDA | 103.60M | 74.45M | 305.64M | 456.59M | 603.82M | 560.20M |
| Net Income | 14.17M | 14.17M | 250.70M | -23.87M | 459.63M | 476.58M |
Balance Sheet | ||||||
| Total Assets | 3.37B | 3.37B | 3.10B | 2.58B | 2.40B | 1.76B |
| Cash, Cash Equivalents and Short-Term Investments | 145.59M | 145.59M | 394.00M | 622.91M | 282.17M | 71.93M |
| Total Debt | 576.49M | 576.49M | 534.25M | 194.04M | 133.06M | 36.38M |
| Total Liabilities | 879.53M | 879.53M | 786.06M | 569.79M | 567.89M | 633.07M |
| Stockholders Equity | 2.49B | 2.49B | 2.32B | 2.01B | 1.83B | 1.13B |
Cash Flow | ||||||
| Free Cash Flow | 25.78M | -451.69M | -589.01M | 32.97M | -89.05M | 68.00M |
| Operating Cash Flow | 149.66M | -82.44M | -377.82M | 48.66M | 60.75M | 341.44M |
| Investing Cash Flow | -167.16M | -207.79M | -217.64M | -10.46M | -105.65M | -284.48M |
| Financing Cash Flow | 11.99M | 41.82M | 366.55M | 302.54M | 255.13M | -1.63M |
Balaxi Pharmaceuticals Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAXI, the sentiment is Positive. The current price of 23.44 is above the 20-day moving average (MA) of 21.25, above the 50-day MA of 22.39, and above the 200-day MA of 23.08, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 63.43 is Neutral, neither overbought nor oversold. The STOCH value of 75.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BALAXI.
Balaxi Pharmaceuticals Limited Peers Comparison
Overall Rating
IN:PAR73Outperform
IN:ALPA54Neutral
IN:BALPHARMA53Neutral
IN:BALAXI44Neutral
IN:NATCAPSUQ34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 1.46B | 11.27 | ― | ― | 9.40% | 34.12% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 54Neutral | INR 1.17B | 33.08 | ― | ― | 0.46% | -83.31% | |
| 53Neutral | INR 1.43B | 18.27 | ― | 1.33% | 18.79% | -2.58% | |
| 44Neutral | INR 1.29B | 37.90 | ― | ― | ― | ― | |
| 34Underperform | INR 1.63B | -6.96 | ― | ― | 8.84% | -285.42% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:BALAXI | Balaxi Pharmaceuticals Limited | 23.44 | -12.48 | -34.74% | |
| IN:ALPA | Alpa Laboratories Limited | 55.61 | -24.36 | -30.46% | |
| IN:BALPHARMA | Bal Pharma Limited | 90.10 | 11.30 | 14.34% | |
| IN:PAR | Par Drugs and Chemicals Limited | 119.00 | 24.89 | 26.45% | |
| IN:NATCAPSUQ | Natural Capsules Limited | 156.10 | -37.30 | -19.29% | |
| IN:BI | Bilcare Ltd | 83.01 | -5.14 | -5.83% |
Balaxi Pharmaceuticals Limited Corporate Events
Balaxi Pharma Reports Nil Physical Share Transfer Re-Lodgement Requests for September 2026
Balaxi Pharmaceuticals Limited has submitted a registrar and transfer agent report to the National Stock Exchange of India on the status of re-lodgement requests for transfer of physical shares, as mandated by a SEBI circular issued in January 2026....
Balaxi Pharmaceuticals Closes Trading Window Ahead of September 2026 Results
Balaxi Pharmaceuticals Limited has announced the closure of its trading window for designated persons and their immediate relatives from October 1, 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code o...
Balaxi Pharma Shareholders Clear Second Term for Independent Director Akshita Ostwal
Balaxi Pharmaceuticals Limited has announced that its shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director at the company’s 83rd Annual General Meeting held on 24 August 2026. Her second term on the board will run...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 30, 2026
